TrialMedical oncology (Northwood, London, England)2015

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.

Yasuyoshi Miyata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.